Glenmark’s Teneligliptin is now available at a cost which is 55% lower than most gliptins in the country

• Gliptins globally is fast becoming the most preferred option to manage Type-2 Diabetes
• Glenmark’s Teneligliptin is the only gliptin to be manufactured in India from API to formulation. All other Gliptins are presently being imported
• Glenmark commences immediate roll-out of the product across Chennai and  Tamil Nadu

 Chennai, Tuesday, August 25, 2015: Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company today announced launch of Teneligliptin in the state of Tamil Nadu. Teneligliptin, a new third generation oral anti-diabetic agent is used for the management of Type-2 Diabetes mellitus. Globally gliptins is emerging as the preferred line of treatment for managing Type-2 Diabetes. Teneligliptin has been highly effective in decreasing postprandial glucose levels, amount of glucose in the blood after meals, as well as fasting blood glucose levels, with a once-a-day administration.

Glenmark has launched this molecule under two brands – Ziten and Zita Plus at a breakthrough price of Rs. 19.90 per tablet per day treatment. Thus the launch of these two products will lower the daily cost of treatment for a Diabetes patient on gliptin therapy by approximately 55%. Most gliptins are priced at around Rs. 45 per day treatment. This translates into a saving of approximately Rs. 9,000 per year for Diabetes patients with the introduction of Teneligliptin.

Glenmark received approval from DCGI for Teneligliptin after conducting clinical trials on the molecule for over 2 years as per the regulatory requirements. . Glenmark’s Teneligliptin is the only gliptin which is available at a lowest cost among all other gliptins being marketed in India while other gliptins are presently being imported.

“Glenmark is proud to be introducing Teneligliptin, an advanced form of treatment for Diabetes at a significantly affordable cost in Tamil Nadu. Through this we will be playing a major role in making anti-diabetics treatment more effective and affordable for thousands of patients across the state”; said Sujesh Vasudevan, President & Head – India Business, Glenmark Pharmaceuticals. He added “Gliptins, although a preferred choice of healthcare professionals is out of reach of many patients because of its high price. By offering Teneligliptin at this price, we aspire to bring many more patients in the advanced gliptin therapy fold.”

For Teneligliptin roll out, Glenmark plans to reach out to close to 2500 Diabetologists, Endocrinologists and other Consulting Physicians in Tamil Nadu. In Chennai alone, the company will be targeting close to 1000 Specialists and informing them about the positive benefits of this new molecule.

India is set to be the Diabetes capital of the world. In 2014, 66.8 million cases of Diabetes were reported giving overall national prevalence of 8.63% (IDF 2014). It is estimated that by the year 2035, 110 million patients will be suffering from Diabetes in India (IDF 2014). In Chennai, approximately 24.5% of adult population suffers from diabetes (ASSOCHAM Report – Nov 2014).

Serious long-term diabetes complications include cardiovascular disease, stroke, chronic kidney failure, foot ulcers, and damage to the eyes (WHO Fact sheet January 2015). Presently, only 1 million out of the total Diabetes patient population are estimated to be presently on gliptins. Hence, the launch of Teneligliptin will significantly help millions of patients who could not afford gliptin treatment due to the high cost.

Gliptins have emerged as a highly popular anti-diabetic therapy and are considered the future of anti-diabetic treatment.  Gliptins are safe and well tolerated, are weight neutral, have low risk of Hypoglycaemia and are equally efficacious with rare side effects compared to other gliptins (ADA 2014).

Teneligliptin is a selective DPP4 inhibitor that is used in the treatment of Type-2 Diabetes mellitus when satisfactory improvement cannot be achieved through diet and exercise, or in combination of diet and exercise. Without any dose modification it can be safely used in renal and hepatic insufficiencies due to balanced excretion through dual route. Teneligliptin suppresses glucagon release and increases insulin release, subsequently lowering blood-glucose levels by selectively inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates glucagon-like peptide-1 (GLP-1), a hormone excreted from the gastrointestinal track in response to food. Teneligliptin with its potent and sustained action has made it highly effective in lowering each of the blood glucose postprandial levels, as well as fasting blood glucose levels, with once-a-day administration.

About Glenmark Pharmaceuticals Ltd:

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma& Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers.

For further information, please contact:

Rajdeep Barooah/ Shibani Shah

Tel: [+91 22] 40189984/1348

Email: corpcomm@glenmarkpharma.com